{
  "ticker": "JNJ",
  "target_date": "2025-01-23",
  "actual_date": "2025-01-23",
  "collected_at": "2025-12-08T11:18:49.137684",
  "price": {
    "open": 141.12,
    "high": 143.52,
    "low": 140.51,
    "close": 142.28456115722656,
    "volume": 10506400,
    "change_1d_pct": 0.94,
    "change_7d_pct": 1.5,
    "change_30d_pct": -1.79
  },
  "technicals": {
    "rsi_14": 55.09,
    "sma_20": 140.75,
    "sma_50": 143.97,
    "macd": -0.443,
    "macd_signal": -1.032,
    "macd_histogram": 0.589,
    "bb_upper": 143.89,
    "bb_lower": 137.61,
    "price_vs_sma20_pct": 1.09,
    "price_vs_sma50_pct": -1.17,
    "volume_ratio": 1.26
  },
  "fundamentals": {
    "market_cap": 489014362112,
    "pe_ratio": 19.59169,
    "forward_pe": 19.148102,
    "price_to_book": 6.160497,
    "price_to_sales": 5.306779,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.33,
    "pct_from_52w_low": 44.28
  },
  "macro": {
    "spy": {
      "price": 604.45,
      "change_1d_pct": 0.55,
      "change_7d_pct": 4.73
    },
    "vix": {
      "level": 15.02,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.64
    },
    "dollar_index": {
      "level": 108.05
    },
    "gold": {
      "price": 2763.1
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "Kura Oncology: Sentiment Is Too Negative",
      "source": "SeekingAlpha",
      "datetime": 1737644120,
      "summary": "Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive acquisition target despite its promising AML drug candidate ziftomenib.",
      "url": "https://finnhub.io/api/news?id=46441af9688d4fa33268aee576f15c513d161762142ba0239f85a6ecea546cba"
    },
    {
      "headline": "UnitedHealth, Caterpillar share gains contribute to Dow's 250-point jump",
      "source": "MarketWatch",
      "datetime": 1737631380,
      "summary": "UnitedHealth, Caterpillar share gains contribute to Dow's 250-point jump",
      "url": "https://finnhub.io/api/news?id=f36eb0c33cad82c82570ef34c504209467aa988759750916a643ad2d0181d933"
    },
    {
      "headline": "JPMorgan Chase, Goldman Sachs share gains lead Dow's 125-point jump",
      "source": "MarketWatch",
      "datetime": 1737625560,
      "summary": "JPMorgan Chase, Goldman Sachs share gains lead Dow's 125-point jump",
      "url": "https://finnhub.io/api/news?id=e1b62d74109900299afcb2f06238cbe1352e74b98831ada284edd91f36e9f142"
    },
    {
      "headline": "J&J: positive results in generalized myasthenia gravis",
      "source": "Finnhub",
      "datetime": 1737625394,
      "summary": "Johnson & Johnson reports that The Lancet Neurology has published the results of a Phase 3 study of nipocalimab, evaluated in a large population of antibody-positive adults with generalized...",
      "url": "https://finnhub.io/api/news?id=34d236957b59984f0f38bc16ea16c6e4ddc0bb7bcfcfea812d2076e4de517f75"
    },
    {
      "headline": "Johnson & Johnson exceeds expectations for fourth quarter",
      "source": "Finnhub",
      "datetime": 1737622903,
      "summary": "Copyright \u00a9 BusinessAMBE 2023Key takeawaysJohnson & Johnson reported $22.5 billion in revenue and adjusted earnings per share of $2.04.Darzalex sales increased 20 percent to $3.08...",
      "url": "https://finnhub.io/api/news?id=205b4b99f58f2a390c8c5e6ef72a8d418fa3b87e7a59bbad2911107285f4a87d"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "8-K",
      "date": "2025-01-22",
      "description": "jnj-20250122.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000003/jnj-20250122.htm"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734042449.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000106/xslF345X05/wk-form4_1734042449.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041779.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000104/xslF345X05/wk-form4_1734041779.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041373.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000102/xslF345X05/wk-form4_1734041373.xml"
    },
    {
      "form": "13F-HR",
      "date": "2024-11-13",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445424000604/xslForm13F_X02/primary_doc.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}